70 related articles for article (PubMed ID: 38671526)
1. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.
Poiset SJ; Shah S; Cappelli L; Anné P; Mooney KE; Werner-Wasik M; Laufer TS; Posey JA; Lin D; Basu Mallick A; Lavu H; Bashir B; Yeo CJ; Mueller AC
Radiat Oncol; 2024 May; 19(1):65. PubMed ID: 38812040
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
Liu HY; Lee YD; Sridharan S; Choong ES; Le H; Wang W; Khor R; Chu J; Oar A; Mott R; Smart J; Jenkins T; Anderson N; Cross S; Loo KF; Wigg A; Stuart K; Pryor D
J Med Imaging Radiat Oncol; 2021 Jun; 65(3):365-373. PubMed ID: 33890425
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma.
Feng XY; Li J; Li AM; Jing SH; Zhu XX; Wang Z
World J Surg Oncol; 2022 Sep; 20(1):322. PubMed ID: 36171617
[TBL] [Abstract][Full Text] [Related]
4. REPeated mAgnetic resonance Image-guided stereotactic body Radiotherapy (MRIg-reSBRT) for oligometastatic patients: REPAIR, a mono-institutional retrospective study.
Chiloiro G; Panza G; Boldrini L; Romano A; Placidi L; Nardini M; Galetto M; Votta C; Campitelli M; Cellini F; Massaccesi M; Gambacorta MA
Radiat Oncol; 2024 Apr; 19(1):52. PubMed ID: 38671526
[TBL] [Abstract][Full Text] [Related]
5. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
6. Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis.
Stera S; Balermpas P; Chan MKH; Huttenlocher S; Wurster S; Keller C; Imhoff D; Rades D; Dunst J; Rödel C; Hildebrandt G; Blanck O
Strahlenther Onkol; 2018 Feb; 194(2):143-155. PubMed ID: 28875297
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
[TBL] [Abstract][Full Text] [Related]
9. Functional image-guided stereotactic body radiation therapy planning for patients with hepatocellular carcinoma.
Tsegmed U; Kimura T; Nakashima T; Nakamura Y; Higaki T; Imano N; Doi Y; Kenjo M; Ozawa S; Murakami Y; Awai K; Nagata Y
Med Dosim; 2017 Summer; 42(2):97-103. PubMed ID: 28433483
[TBL] [Abstract][Full Text] [Related]
10. Exploring the efficacy of multi-flavored feature extraction with radiomics and deep features for prostate cancer grading on mpMRI.
Khanfari H; Mehranfar S; Cheki M; Mohammadi Sadr M; Moniri S; Heydarheydari S; Rezaeijo SM
BMC Med Imaging; 2023 Nov; 23(1):195. PubMed ID: 37993801
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis.
Boldrini L; Romano A; Chiloiro G; Corradini S; De Luca V; Verusio V; D'Aviero A; Castelluccia A; Alitto AR; Catucci F; Grimaldi G; Trapp C; Hörner-Rieber J; Marchesano D; Frascino V; Mattiucci GC; Valentini V; Gentile P; Gambacorta MA
Radiat Oncol; 2023 May; 18(1):84. PubMed ID: 37218005
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience.
Chiloiro G; Boldrini L; Romano A; Placidi L; Tran HE; Nardini M; Massaccesi M; Cellini F; Indovina L; Gambacorta MA
Radiol Med; 2023 May; 128(5):619-627. PubMed ID: 37079221
[TBL] [Abstract][Full Text] [Related]
13. Repeat stereotactic body radiotherapy for oligometastatic disease.
Willmann J; Adilovic S; Vlaskou Badra E; Christ SM; Ahmadsei M; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2023 Jul; 184():109671. PubMed ID: 37059336
[TBL] [Abstract][Full Text] [Related]
14. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making.
Andratschke N; Willmann J; Appelt AL; Alyamani N; Balermpas P; Baumert BG; Hurkmans C; Høyer M; Langendijk JA; Kaidar-Person O; van der Linden Y; Meattini I; Niyazi M; Reynaert N; De Ruysscher D; Tanadini-Lang S; Hoskin P; Poortmans P; Nieder C
Lancet Oncol; 2022 Oct; 23(10):e469-e478. PubMed ID: 36174633
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease.
Willmann J; Vlaskou Badra E; Adilovic S; Christ SM; Ahmadsei M; Mayinger M; Guckenberger M; Andratschke N
Clin Transl Radiat Oncol; 2022 Nov; 37():12-18. PubMed ID: 36046333
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
